Selected article for: "current meta analysis and meta analysis"

Author: Siordia, Juan A.; Bernaba, Michael; Yoshino, Kenji; Ulhaque, Abid; Kumar, Sooraj; Bernaba, Mario; Bergin, Edward
Title: Systematic and Statistical Review of Coronavirus Disease 19 Treatment Trials
  • Cord-id: 07tdrd4w
  • Document date: 2020_7_15
  • ID: 07tdrd4w
    Snippet: The following systematic review and meta-analysis compile the current data regarding human controlled COVID-19 treatment trials. An electronic search of the literature compiled studies pertaining to human controlled treatment trials with COVID-19. Medications assessed included lopinavir/ritonavir, arbidol, hydroxychloroquine, tocilizumab, favipiravir, heparin, and dexamethasone. Statistical analyses were performed for common viral clearance endpoints whenever possible. Lopinavir/ritonavir showed
    Document: The following systematic review and meta-analysis compile the current data regarding human controlled COVID-19 treatment trials. An electronic search of the literature compiled studies pertaining to human controlled treatment trials with COVID-19. Medications assessed included lopinavir/ritonavir, arbidol, hydroxychloroquine, tocilizumab, favipiravir, heparin, and dexamethasone. Statistical analyses were performed for common viral clearance endpoints whenever possible. Lopinavir/ritonavir showed no significant effect on viral clearance for COVID-19 cases (OR 0.95 [95% CI 0.50–1.83]). Hydroxychloroquine also showed no significant effect on COVID-19 viral clearance rates (OR 2.16 [95% CI 0.80–5.84]). Arbidol showed no 7-day (OR 1.63 [95% CI 0.76–3.50]) or 14-day viral (OR 5.37 [95% CI 0.35–83.30]) clearance difference compared to lopinavir/ritonavir. Review of literature showed no significant clinical improvement with lopinavir/ritonavir, arbidol, hydroxychloroquine, or remdesivir. Tocilizumab showed mixed results regarding survival. Favipiravir showed quicker symptom improvement compared to lopinavir/ritonavir and arbidol. Heparin and dexamethasone showed improvement with severe COVID-19 cases requiring supplemental oxygenation. Current medications do not show significant effect on COVID-19 viral clearance rates. Tocilizumab showed mixed results regarding survival. Favipiravir shows favorable results compared to other tested medications. Heparin and dexamethasone show benefit especially for severe COVID-19 cases.

    Search related documents:
    Co phrase search for related documents
    • acid level and acute kidney injury: 1
    • acid level and liver function: 1
    • acid level and lopinavir level increase: 1
    • acid level and lopinavir ritonavir: 1
    • acid level and low molecular: 1
    • acid level and low molecular weight: 1
    • acidic potential and action mechanism: 1
    • acidosis type and acute kidney injury: 1, 2
    • acidosis type and liver function: 1
    • action mechanism and adenosine triphosphate: 1, 2
    • action mechanism and liver function: 1
    • action mechanism and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • action mechanism and lopinavir ritonavir hydroxychloroquine: 1, 2
    • action mechanism and low molecular: 1, 2, 3, 4
    • action mechanism and low molecular weight: 1, 2
    • action mechanism and low molecular weight heparin: 1